

50. Miller LS. Bladder cancer. *Cancer*. 1977;39(Suppl):973-980.

51. Hall RR, Newling DWW, Ramsden PD, Richards B, Robinson MRG, Smith PH. Treatment of invasive bladder cancer by local resection and high dose methotrexate. *Br J Urol*. 1984;56:668-672.

52. Srougi M, Simon SD. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year follow-up. *J Urol*. 1994;151:593-597.

53. Dunst J, Sauer R, Schrott K, Kuhn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. *Int J Radiat Oncol Biol Phys*. 1994;30:261-266.

54. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. *J Clin Oncol*. 1993;11:2150-2157.

55. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efrid JT. Selective bladder preservation by combination treatment of invasive bladder cancer. *N Engl J Med*. 1993;329:1377-1382.

56. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. *Int J Radiat Oncol Biol Phys*. 1993;25:783-790.

57. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. *J Clin Oncol*. 1998;16:3576-3583.

58. Shipley WU, Kaufman DS, Heney DM, et al. An update of combined modality therapy for patients with muscle invasive bladder cancer using selective bladder preservation or cystectomy. *J Urol*. 1999;162:445-451.

CORRECTION

In the February issue of the Journal, Table 2 in the article by Bell et al., "Adherence to Antiviral Drug Regimens in HIV-Infected Adolescent Patients" was printed incorrectly. The corrected version is printed below.

Table 2. Means and standard deviations of study variables for all subjects by Adherence group

Variable	N	Total sample Mean ± SD	Adherers (N = 5) Mean ± SD	Non-Adherers (N = 13) Mean ± SD	Non-Medicated (N = 5) Mean ± SD
Age at enrollment	23	19.0 ± 1.4	18.8 ± 1.4	18.8 ± 1.4	19.4 ± 0.9
Prior STD's/preg.	23	2.3 ± .81	2.4 ± .89	2.4 ± .77	1.8 ± .84
Housing and instability	21	1.4 ± .51	1.0 ± 0*	1.6 ± .51*	1.5 ± .58
Months of treatment	23	15.3 ± 14.5	9.0 ± 9.0*	22.1 ± 15.2*	3.8 ± 4.4
Hx of keeping apptmts.	22	1.5 ± .60	1.6 ± .55	1.4 ± .52	1.5 ± 1.0
Viral load					
First visit	14	27.3K ± 57.3K	55.9K ± 106.1K	19.4K ± 23.3K	1.7K ± 1.4K
Last visit	13	19.6K ± 59.9K	499 ± 0	25.3K ± 68.0K	499 ± n/a
Change	10	-12.2K ± 22.2K	-3.5K ± 4.9K	-16.1K ± 26.0K	-2.3K ± n/a
CD-4 value					
First visit	20	414.4 ± 231.0	380.3 ± 145.8	327.7 ± 188.6	708.8 ± 197.5
Last visit	20	398.7 ± 225.8	402.0 ± 205.0	297.9 ± 159.8	697.8 ± 165.6
Change	19	-20.6 ± 134.2	21.8 ± 88.3	-39.5 ± 165.8	-11.0 ± 69.8
Health status change	15	2.6 ± .74	3.0 ± 0	2.4 ± .84	3.0 ± 0

*p <0.05